Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer.
Noblejas-López MDM, Gandullo-Sánchez L, Galán-Moya EM, López-Rosa R, Tébar-García D, Nieto-Jiménez C, Gómez-Juárez M, Burgos M, Pandiella A, Ocaña A. Noblejas-López MDM, et al. Among authors: galan moya em. Int J Mol Sci. 2022 May 13;23(10):5476. doi: 10.3390/ijms23105476. Int J Mol Sci. 2022. PMID: 35628286 Free PMC article.
Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer.
Corrales-Sánchez V, Noblejas-López MDM, Nieto-Jiménez C, Pérez-Peña J, Montero JC, Burgos M, Galán-Moya EM, Pandiella A, Ocaña A. Corrales-Sánchez V, et al. J Cell Mol Med. 2020 Mar;24(5):3117-3127. doi: 10.1111/jcmm.14980. Epub 2020 Feb 7. J Cell Mol Med. 2020. PMID: 32032474 Free PMC article.
MZ1 co-operates with trastuzumab in HER2 positive breast cancer.
Noblejas-López MDM, Nieto-Jiménez C, Galán-Moya EM, Tebar-García D, Montero JC, Pandiella A, Burgos M, Ocaña A. Noblejas-López MDM, et al. J Exp Clin Cancer Res. 2021 Mar 19;40(1):106. doi: 10.1186/s13046-021-01907-9. J Exp Clin Cancer Res. 2021. PMID: 33741018 Free PMC article.
Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis.
Burgos M, Cavero-Redondo I, Álvarez-Bueno C, Galán-Moya EM, Pandiella A, Amir E, Ocaña A. Burgos M, et al. Among authors: galan moya em. Ther Adv Med Oncol. 2022 Jan 19;14:17588359211072621. doi: 10.1177/17588359211072621. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35082925 Free PMC article.
Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer.
Nieto-Jimenez C, Galan-Moya EM, Corrales-Sanchez V, Noblejas-Lopez MDM, Burgos M, Domingo B, Montero JC, Gomez-Juarez M, Picazo-Martinez MG, Esparis-Ogando A, Pandiella A, Ocaña A. Nieto-Jimenez C, et al. Cancer Lett. 2020 Oct 28;491:50-59. doi: 10.1016/j.canlet.2020.06.020. Epub 2020 Jul 28. Cancer Lett. 2020. PMID: 32735909 Free article.
46 results